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Introduction {#sec001}
============

Gestational Diabetes *Mellitus* (GDM) is the most frequent metabolic disorder of pregnancy, affecting between 1--14% of all women \[[@pone.0144027.ref001]\]. The prevalence of GDM is expected to increase substantially over the next years with the adoption of new diagnostic criteria recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and also due to the increasing prevalence of obesity among reproductive age women \[[@pone.0144027.ref002], [@pone.0144027.ref003]\].

The complications associated with GDM can be reduced with adequate glycemic control \[[@pone.0144027.ref004]\]. While most women with GDM will achieve adequate glycemic control with diet and exercise, a proportion of them will require antenatal insulin treatment (AIT) \[[@pone.0144027.ref005]\]. The need for insulin characterizes patients with a more severe form of GDM, who will have an increased probability of developing type 2 Diabetes *Mellitus* (T2DM) and cardiovascular complications in the future \[[@pone.0144027.ref006], [@pone.0144027.ref007]\]. These two forms of GDM seem to reflect different degrees of beta cell dysfunction or different pathophysiological mechanisms \[[@pone.0144027.ref008]\].

During pregnancy, insulin resistance (IR) and hyperlipidemia are important physiological processes that are essential to ensure adequate fetal nutrition. In the third trimester of pregnancy, healthy women have major changes in their lipid metabolism that lead to increased plasma triacylglycerol levels and, to a lesser extent, to higher phospholipid and cholesterol levels \[[@pone.0144027.ref009]\].

Besides acting as a form of energy storage, lipids are an important component of membranes and have many other key functions including their role in signaling pathways and the regulation of other molecules. Imbalances in lipid signaling pathways are associated with inflammation progression, autoimmunity and several systemic diseases, such as the metabolic syndrome, atherosclerosis and hypertension \[[@pone.0144027.ref010]\].

High triglycerides plasma levels are associated with IR/T2DM but this increase is influenced by glycemic levels. Patients with well-controlled T2DM have triglyceride levels similar to healthy controls \[[@pone.0144027.ref011]\]. In contrast, patients with T2DM, even with adequate metabolic control, have lower HDL cholesterol, free cholesterol levels and phospholipids on the HDL surface \[[@pone.0144027.ref012]\].

There are conflicting results regarding hyperlipidemia in GDM. While some investigators report significantly higher lipid levels in all trimesters in GDM patients compared to healthy pregnant women, others refute these findings \[[@pone.0144027.ref009], [@pone.0144027.ref013]\]. Herrera and Ortega-Senovilla (2010) highlighted these controversies in their review of studies on the lipid profile of GDM patients \[[@pone.0144027.ref009]\].

With the advent of new methods, it is now possible to perform more sensitive and specific lipid analyses in extracts of cells and tissues. Lipid fingerprinting is useful because it allows the identification of a lipid profile that could be associated with a specific disease. Liquid chromatography (LC) coupled with electrospray ionization (ESI)-quadrapole time of flight hybrid mass spectrometer (QTOF-MS) allows the identification of complex molecular species \[[@pone.0144027.ref014]\]. It is well documented that ESI/MS is very useful and efficient for the study of lipids in many diseases. Moreover, this technique allows a direct analysis of the lipid profile of chloroform extracts \[[@pone.0144027.ref015]\]. Previous investigations in T2DM suggest that this technique is able to detect dyslipidemia associated with that condition \[[@pone.0144027.ref016], [@pone.0144027.ref017]\].

There is evidence indicating that glycemic control affects lipid concentrations. Giuffrida et al. (2012) reported an association between HbA1~c~ levels and changes in lipid profile in patients with type 1 Diabetes *Mellitus* (T1DM) \[[@pone.0144027.ref018]\]. In contrast, Karkkainen et al. (2013) did not detect significant differences in cholesterol, LDL, HDL and triglyceride levels in samples from third trimester patients with GDM treated with diet or insulin when compared with healthy pregnant women. However, there were significant differences between the groups after delivery \[[@pone.0144027.ref019]\].

The search for markers that could predict which women will develop the more severe form of GDM has been the focus of several studies \[[@pone.0144027.ref020]--[@pone.0144027.ref022]\]. This quest is based on the premise that it would be useful to predict which women will develop more severe forms of the disease in order to improve efficiency of health care delivery in GDM and thus optimize maternal and perinatal outcomes in these cases. However, until now, there are no tools that can help to predict this risk and this may in part be due to the lack of studies on possible differences in the physiopathology of milder versus more severe forms of GDM. The aim of our study was to use a lipid fingerprinting approach to analyze the blood serum lipid profile of patients with GDM treated with diet or with insulin, in comparison with healthy pregnant women. To the best of our knowledge, up to the moment, this approach has not been used for lipid analyses in patients with GDM. We hope that our findings will contribute to the understanding of GDM physiopathology and to the future development of new tools for the early prediction of which women will develop more severe forms of the disease.

Materials and Methods {#sec002}
=====================

This cross-sectional analytical study recruited women in the antenatal clinics of two public tertiary teaching facilities in Sao Paulo, Brazil (Dr. Mario de Moraes Altenfelder Silva maternity and Sao Paulo hospital). The study was approved by Ethics in Research Committee of Universidade Federal de São Paulo/Hospital São Paulo (\#0704/11) and Ethics in Research Committee of Dr. Mario de Moraes Altenfelder Silva Maternity (\#02/12) and written informed consent was obtained from all participants.

The inclusion criteria were singleton pregnancy with a live fetus and gestational age between 30 to 36 6/7 weeks, based on obstetric sonogram performed before the 20^th^ week of pregnancy. Women with any of the following were excluded: pre-existing Diabetes *Mellitus* (type 1 or type 2); chronic systemic autoimmune pre-existing diseases; acute or chronic active infections; solid organ transplant recipients and women using steroids, antibiotics, immunosuppressants, antihistamines or anti-inflammatory medication. Women with obstetric disorders (including but not limited to pre-eclampsia, premature rupture of membranes, preterm labor or placenta previa) were also excluded.

Participants were divided into three groups: healthy pregnant women (controls, n = 30), women diagnosed with GDM adequately controlled with diet (diet-treated GDM, n = 30) and women with GDM that required antenatal insulin treatment (AIT) to control glycemic levels (AIT-GDM, n = 30). All participants had been tested for GDM at 24--28 weeks through a 2-hours, 75g oral glucose tolerance test, as part of their routine antenatal care in the two settings. Women were diagnosed with GDM according to the IADPSG recommendations, i.e. fasting glucose between 92 and \< 126 mg/dL and/or 1-hr post 75 g load ≥ 180 mg/dL and/or 2-hr post 75 g load between 153--199 mg/dL \[[@pone.0144027.ref002]\]. Pre-pregnancy body mass index (BMI) was calculated based on measured height and self-reported pre-pregnancy weight. Race was self-reported.

Upon enrolment, 8 mL of peripheral blood was collected from each participant, regardless of diet, in tubes containing spray-coated silica and a polymer gel (SST) for serum separation (BD Diagnostics). After clot retraction, the sample was centrifuged at 2,205 xg for 10 minutes at room temperature to obtain serum sample, which was immediately frozen at -80°C.

Lipid extraction {#sec003}
----------------

Lipid extraction was performed according to the Bligh and Dyer protocol \[[@pone.0144027.ref023]\] with some modifications. Briefly, 50 μL of distilled water (HPLC grade- Sigma-Aldrich, St. Louis, MO, USA) was added to 50 μL of serum. Then, 127 μL of chloroform (HPLC grade- Merck, Darmstadt, Germany) and 252 μL of methanol (HPLC grade- Sigma-Aldrich) were added. After homogenization by vortexing, 100 μL of water and 127 μl of chloroform were added for polar and apolar phases separation. The mixture was centrifuged at 800 xg for 5 minutes at room temperature and 200 μL of the lower layer containing lipids were transferred to another LC-MS glass tube (Waters, Milford, MA, USA). After drying the entire liquid content, the samples were stored at -80°C until analysis.

ESI-(+)-MS analyses {#sec004}
-------------------

Each sample was analyzed in triplicate. For analysis, the samples were suspended in 100 μL of a 1:1 methanol:water solution and then filtered using a 0.22 μm filter (Merck Millipore Corporation, Billerica, MA, USA). Analyses were performed on a hybrid high-resolution mass spectrometer Q-TOF Ultima Waters (Manchester, England) with Electrospray as the ionization source, in positive mode. The analysis conditions were: source temperature of 150°C, desolvation temperature of 450°C, capillary voltage of 3 kV and cone voltage equal to 35 V. The nitrogen flow in the cone was 50 L.h^-1^ and of desolvation was 550 L.h^-1^. The m/z range acquired was between 500--1200. The equipment was calibrated with a 5 mM sodium formate solution. Chromatography was performed with an Acquity chromatograph (Waters, Manchester, England) with a reverse phase column (Acquity HSS UPLC 1.8 μm, 2.1 x 100 mm) conditioned to 35°C. The flow rate was 0.5 mL.min^-1^. The elution buffers were A: acetonitrile doped with 0.1% formic acid and B: water with 0.1% formic acid.

Data analysis {#sec005}
-------------

MassLynx 4.1 software (Waters, Manchester, UK) was used for the preprocessing of mass spectra obtained by ESI-MS. Each sample spectrum was processed for background removal and smoothing and for peaks centroiding.

The intensity values were normalized by cubic Pareto scaling and scaling transformation. Statistical analysis was performed using MetaboAnalyst 2.0 software ([http://www.metaboanalyst.ca](http://www.metaboanalyst.ca/)). Univariate (One-way ANOVA) and multivariate (principal component analysis \[PCA\] and discriminant analysis by partial least squares \[PLS-DA\]) analyses workflows were applied to the data set. An alpha error of 5% was adopted.

The PLS-DA models were built and the variable importance in the projection (VIP) was used to identify the ions that had greater discriminatory effect between the groups in the component with higher power projection. Considering the masses of the differentially expressed ions, the lipids were identified with the aid of SimLipid 3.0 software (PREMIER Biosoft, Palo Alto, CA, USA), with a maximum acceptable error of 50ppm, positive polarity (M+H, M+Na and M+K) and selecting only the following categories: Glycerophospholipids (GP), Sphingolipids (SP), Fatty Acyls (FA), Glycerolipids (GL), Sterol Lipids (ST) and Prenol Lipids (PR). Moreover, the criteria for the selection of the best lipid category of each ion were: between H^+^ and Na^+^ polarity, we chose the one with the lowest mass error; the K^+^ polarity was chosen only in cases where there were no H^+^ or Na^+^ polarity ions, and in these cases, the one with the lowest mass error.

The chi-square test was used to compare categorical variables. The Kolmogorov--Smirnov or Shapiro--Wilk tests and Skewness and Kurtosis values were used to assess the distribution of continuous numerical variables. For analysis of variance between groups, the one-way ANOVA test was used, followed by a Tukey post-hoc test. All tests were considered significant at p\<0.05. Statistical analyses were performed with standard software (GraphPad Prism 5 for Windows).

Results {#sec006}
=======

[Table 1](#pone.0144027.t001){ref-type="table"} presents the main characteristics of the 90 participants. Healthy controls were significantly younger than diet-treated GDM patients (p\<0.01) and patients with AIT-GDM (p\<0.0001). Controls were also significantly leaner than GDM patients (p\<0.0001).

10.1371/journal.pone.0144027.t001

###### Main characteristics of 90 pregnant women.

![](pone.0144027.t001){#pone.0144027.t001g}

  Variable                      Controls N = 30   Diet-treated GDM N = 30                        Insulin-treated GDM N = 30                     p
  ----------------------------- ----------------- ---------------------------------------------- ---------------------------------------------- --------------------------------------------------
  Race                                                                                                                                          
  White                         10 (33%)          13 (43%)                                       12 (40%)                                       
  Mixed                         16 (53%)          14 (47%)                                       12 (40%)                                       0.73[^*a*^](#t001fn002){ref-type="table-fn"}
  Black                         4 (14%)           3 (10%)                                        6 (20%)                                        
  Age (years)                                                                                                                                   
  Mean                          27.2              32.9[^*c*^](#t001fn004){ref-type="table-fn"}   33.0[^*d*^](#t001fn005){ref-type="table-fn"}   \<0.0001[^*b*^](#t001fn003){ref-type="table-fn"}
  SD                            5.2               6.1                                            5.2                                            
  Pre-pregnancy BMI (Kg/m^2^)                                                                                                                   
  Mean                          23.9              28.2[^*d*^](#t001fn005){ref-type="table-fn"}   30.9[^*d*^](#t001fn005){ref-type="table-fn"}   \<0.0001[^*b*^](#t001fn003){ref-type="table-fn"}
  SD                            5.6               4.9                                            5.7                                            
  Parity                                                                                                                                        
  nulliparous                   9 (30%)           9 (30%)                                        6 (20%)                                        0.60[^*a*^](#t001fn002){ref-type="table-fn"}
  multiparous                   21 (70%)          21 (70%)                                       24 (80%)                                       
  GA at collection (weeks)                                                                                                                      
  Mean                          32.9              33.2                                           32.9                                           0.76[^*b*^](#t001fn003){ref-type="table-fn"}
  SD                            1.9               1.9                                            1.9                                            

GDM: Gestational Diabetes *Mellitus*, SD: Standard deviation, BMI: Body Mass Index, GA: Gestational age

^*a*^Chi-square test

^*b*^One-way ANOVA test

^*c*^p\<0.01 versus Control

^*d*^p\<0.0001 versus Control

The representative spectra of each group are shown in [Fig 1A](#pone.0144027.g001){ref-type="fig"}. One-way ANOVA analysis revealed 143 statistical significant ions, of which 93 were identified ([Table 2](#pone.0144027.t002){ref-type="table"}). Of these, 4 were Fatty Acyls (FA), 1 Glycerolipid (GL), 63 Glycerophopholipids (GP), 5 Prenol Lipids (PR), 5 Sphingolipids (SL) and 15 Sterol Lipids (ST). Tukey's HSD post-hoc test detected differences among the groups, but it was not possible to identify in which group the representation of each ion was higher or lower. A total of 14 ions (1 FA, 1 GL, 11 GP and 1 ST) characterized the diet-treated GDM group (diet-treated GDM x control). A total of 18 ions (10 GP, 2 PR, 2 SP and 4 SL) were differentially represented in the AIT-GDM group. There were 7 ions (5 GP and 2 ST) differentially represented in the two forms of GDM (diet-treated GDM versus AIT-GDM).

![Serum lipid profile of healthy pregnant women and women with milder and more severe forms of GDM.\
**(**A) ESI-MS characteristic spectra of healthy controls, diet-treated GDM and insulin- treated groups. (B) 3D score plot between the selected principal components. (C) Important features identified by PLS-DA. The colored boxes on the right indicate the relative concentrations of the corresponding metabolite in each group under study. Group 0 = Control; Group 1 = Diet-treated GDM; Group 2 = Insulin-treated GDM.](pone.0144027.g001){#pone.0144027.g001}

10.1371/journal.pone.0144027.t002

###### Identified ions revealed by One-way ANOVA, sorting by Tukey's HSD post-hoc test.

![](pone.0144027.t002){#pone.0144027.t002g}

  Mass (*m/z*)    Category               Formula                   p value      Tukey\'s HSD
  --------------- ---------------------- ------------------------- ------------ ------------------
  **599.5127**    Fatty Acyls            C~38~H~72~O~2~            0.023161     1--0
  **603.5169**    Glycerolipids          C~37~H~72~O~4~            0.048001     1--0
  **533.2781**    Glycerophospholipids   C~24~H~47~O~9~P           0.028454     1--0
  **662.3447**    Glycerophospholipids   C~30~H~58~NO~10~P         0.0024812    1--0
  **689.5498**    Glycerophospholipids   C~39~H~77~O~7~P           0.031083     1--0
  **718.5735**    Glycerophospholipids   C~40~H~80~NO~7~P          0.042917     1--0
  **721.3664**    Glycerophospholipids   C~33~H~63~O~13~P          0.044215     1--0
  **749.5307**    Glycerophospholipids   C~40~H~77~O~10~P          0.015158     1--0
  **756.6054**    Glycerophospholipids   C~43~H~82~NO~7~P          0.023612     1--0
  **794.6333**    Glycerophospholipids   C~46~H~84~NO~7~P          0.035427     1--0
  **850.6029**    Glycerophospholipids   C~48~H~84~NO~9~P          0.019524     1--0
  **981.4979**    Glycerophospholipids   C~53~H~83~O~13~P          0.036555     1--0
  **1003.5222**   Glycerophospholipids   C~53~H~89~O~13~P          0.031282     1--0
  **713.3889**    Sterol Lipids          C~36~H~56~O~14~           0.033264     1--0
  **506.2777**    Glycerophospholipids   C~22~H~46~NO~8~P          0.0017259    2--0
  **544.3917**    Glycerophospholipids   C~27~H~56~NO~6~P          0.0094764    2--0
  **586.3184**    Glycerophospholipids   C~28~H~54~NO~7~P          0.0018382    2--0
  **606.3403**    Glycerophospholipids   C~27~H~54~NO~9~P          0.023815     2--0
  **632.4543**    Glycerophospholipids   C~33~H~62~NO~8~P          0.0043383    2--0
  **660.386**     Glycerophospholipids   C~31~H~60~NO~10~P         0.00017847   2--0
  **675.53**      Glycerophospholipids   C~38~H~75~O~7~P           0.00064645   2--0
  **812.6175**    Glycerophospholipids   C~46~H~86~NO~8~P          0.04182      2--0
  **844.5894**    Glycerophospholipids   C~49~H~82~NO~8~P          0.003992     2--0
  **884.5675**    Glycerophospholipids   C~50~H~78~NO~10~P         0.02529      2--0
  **531.3707**    Prenol Lipids          C~32~H~50~O~6~            0.0038973    2--0
  **943.478**     Prenol Lipids          C~52~H~72~O~14~           0.02148      2--0
  **824.5521**    Sphingolipids          C~42~H~81~NO~12~S         0.028795     2--0
  **991.6659**    Sphingolipids          C~51~H~94~N~2~O~16~       0.0063787    2--0
  **507.3635**    Sterol Lipids          C~31~H~48~O~4~            0.0094738    2--0
  **558.3406**    Sterol Lipids          C~29~H~51~NO~7~S          0.0073947    2--0
  **933.4854**    Sterol Lipids          C~46~H~76~O~19~           0.0040151    2--0
  **1047.6096**   Sterol Lipids          C~52~H~86~O~21~           0.0015661    2--0
  **585.3006**    Glycerophospholipids   C~26~H~49~O~12~P          0.0036497    2--1
  **619.3145**    Glycerophospholipids   C~29~H~47~O~12~P          0.015053     2--1
  **661.4505**    Glycerophospholipids   C~36~H~69~O~8~P           0.034327     2--1
  **842.4538**    Glycerophospholipids   C~45~H~74~NO~10~P         0.027476     2--1
  **961.5004**    Glycerophospholipids   C~50~H~83~O~13~P          0.018855     2--1
  **595.3661**    Sterol Lipids          C~34~H~52~O~7~            0.0014459    2--1
  **763.3888**    Sterol Lipids          C~39~H~64~O~13~           0.037829     2--1
  **527.2826**    Fatty Acyls            C~23~H~42~O~13~           2.24E-05     1--0; 2--0
  **518.3728**    Glycerophospholipids   C~25~H~54~NO~6~P          0.0012904    1--0; 2--0
  **528.2808**    Glycerophospholipids   C~25~H~48~NO~7~P          0.011041     1--0; 2--0
  **532.2779**    Glycerophospholipids   C~23~H~44~NO~9~P          0.0015486    1--0; 2--0
  **685.474**     Glycerophospholipids   C~36~H~71~O~8~P           0.00066563   1--0; 2--0
  **701.5422**    Glycerophospholipids   C~40~H~77~O~7~P           2.70E-05     1--0; 2--0
  **703.5581**    Glycerophospholipids   C~40~H~79~O~7~P           0.0022506    1--0; 2--0
  **708.5282**    Glycerophospholipids   C~37~H~74~NO~9~P          0.0047033    1--0; 2--0
  **720.4177**    Glycerophospholipids   C~35~H~69~O~8~PS          0.021746     1--0; 2--0
  **746.4401**    Glycerophospholipids   C~40~H~70~NO~8~P          0.0081335    1--0; 2--0
  **758.6159**    Glycerophospholipids   C~43~H~84~NO~7~P          0.00053932   1--0; 2--0
  **765.5005**    Glycerophospholipids   C~39~H~73~O~12~P          3.41E-14     1--0; 2--0
  **772.4843**    Glycerophospholipids   C~42~H~72~NO~8~P          2.96E-08     1--0; 2--0
  **806.6279**    Glycerophospholipids   C~44~H~88~NO~9~P          7.35E-05     1--0; 2--0
  **828.6145**    Glycerophospholipids   C~46~H~86~NO~9~P          0.00010221   1--0; 2--0
  **900.5578**    Glycerophospholipids   C~52~H~80~NO~8~P          1.52E-05     1--0; 2--0
  **975.5241**    Glycerophospholipids   C~46~H~82~O~16~P~2~       1.97E-19     1--0; 2--0
  **976.5331**    Glycerophospholipids   C~44~H~81~N~3~O~15~P~2~   1.40E-12     1--0; 2--0
  **601.5148**    Prenol Lipids          C~42~H~64~O~2~            0.00023122   1--0; 2--0
  **944.5478**    Sphingolipids          C~48~H~91~NO~12~S         0.0010416    1--0; 2--0
  **1112.6483**   Sphingolipids          C~55~H~101~NO~21~         0.00011821   1--0; 2--0
  **555.2986**    Sterol Lipids          C~27~H~48~O~8~S           1.77E-06     1--0; 2--0
  **573.3884**    Sterol Lipids          C~34~H~52~O~7~            0.0036142    1--0; 2--0
  **588.3636**    Glycerophospholipids   C~28~H~56~NO~8~P          1.13E-07     1--0; 2--0; 2--1
  **614.3744**    Glycerophospholipids   C~30~H~58~NO~8~P          2.81E-08     1--0; 2--0; 2--1
  **898.5402**    Glycerophospholipids   C~50~H~86~NO~8~P          6.10E-08     1--0; 2--0; 2--1
  **575.5295**    Fatty Acyls            C~36~H~72~O~3~            0.0056344    1--0; 2--1
  **608.4196**    Glycerophospholipids   C~31~H~62~NO~8~P          0.0035127    1--0; 2--1
  **639.3997**    Glycerophospholipids   C~33~H~61~O~8~P           0.00010065   1--0; 2--1
  **694.4318**    Glycerophospholipids   C~36~H~66~NO~8~P          0.00036177   1--0; 2--1
  **744.6102**    Glycerophospholipids   C~42~H~82~NO~7~P          8.67E-05     1--0; 2--1
  **653.3326**    Prenol Lipids          C~39~H~50~O~7~            0.0065297    1--0; 2--1
  **529.312**     Sterol Lipids          C~29~H~46~O~7~            7.95E-05     1--0; 2--1
  **515.2811**    Fatty Acyl             C~25~H~42~N~2~O~7~S       0.001328     2--0; 2--1
  **530.3062**    Glycerophospholipids   C~25~H~50~NO~7~P          0.00032057   2--0; 2--1
  **568.3717**    Glycerophospholipids   C~27~H~54~NO~9~P          2.06E-06     2--0; 2--1
  **578.2951**    Glycerophospholipids   C~25~H~50~NO~9~P          0.0012762    2--0; 2--1
  **672.4383**    Glycerophospholipids   C~34~H~68~NO~8~P          0.00032939   2--0; 2--1
  **739.4805**    Glycerophospholipids   C~37~H~71~O~12~P          0.00036796   2--0; 2--1
  **820.4806**    Glycerophospholipids   C~43~H~76~NO~10~P         0.0011045    2--0; 2--1
  **872.5091**    Glycerophospholipids   C~47~H~80~NO~10~P         7.66E-05     2--0; 2--1
  **896.4743**    Glycerophospholipids   C~48~H~76~NO~10~P         0.002795     2--0; 2--1
  **899.4582**    Glycerophospholipids   C~47~H~73~O~13~P          0.000357     2--0; 2--1
  **1006.5383**   Glycerophospholipids   C~48~H~85~N~3~O~15~P~2~   0.00010404   2--0; 2--1
  **1028.5152**   Glycerophospholipids   C~48~H~85~N~3~O~15~P~2~   0.014492     2--0; 2--1
  **508.449**     Sphingolipids          C~32~H~61~NO~3~           0.0088719    2--0; 2--1
  **514.2695**    Sterol Lipids          C~26~H~42~NO~7~S          1.02E-06     2--0; 2--1
  **516.2946**    Sterol Lipids          C~26~H~45~NO~7~S          9.04E-07     2--0; 2--1
  **541.2933**    Sterol Lipids          C~27~H~38~F~6~O~4~        0.00017966   2--0; 2--1
  **741.4259**    Sterol Lipids          C~39~H~64~O~13~           0.0030906    2--0; 2--1
  **819.4219**    Sterol Lipids          C~41~H~64~O~15~           0.0070071    2--0; 2--1
  **580.302**     Glycerophospholipids   C~28~H~48~NO~8~P          0.037836     
  **673.4076**    Glycerophospholipids   C~33~H~63~O~10~P          0.047301     
  **623.5099**    Prenol Lipids          C~42~H~64~O~2~            0.040101     

Group 0 = Control; Group 1 = Diet-treated GDM; Group 2 = Insulin-treated GDM.

Twenty-three ions (1 FA, 17 GP, 1 PR, 2 SP and 2 ST) were characteristic of GDM, independent of treatment mode (diet-treated GDM x control and AIT-GDM x control). There were 7 ions (1 FA, 4 GP, 1 PR and 1 ST) specific to the diet-treated GDM group (diet-treated GDM x control and diet-treated GDM x AIT-GDM). On the other hand, 18 ions (1 FA, 11 GP, 1 SP and 5 ST) were differentially represented in the AIT-GDM group (AIT-GDM x control and AIT-GDM x diet-treated GDM). Finally, three ions classified as GP were differentially represented between the three groups. The ANOVA test detected a significant difference in three ions (2 GP and 1 PR) that was not confirmed by the post-hoc test ([Table 2](#pone.0144027.t002){ref-type="table"}).

PCA analysis identified that the five first principal components (PC's) explained 90.4% of the data model variance. Separation between the three groups was achieved by PLS-DA ([Fig 1B](#pone.0144027.g001){ref-type="fig"}). The sixteen most important ions for the discrimination of the groups were selected using the first 3 components ([Fig 1C](#pone.0144027.g001){ref-type="fig"}).

Only 11 ions of identified VIPs were classified: 9 GP and 2 ST ([Table 3](#pone.0144027.t003){ref-type="table"}).

10.1371/journal.pone.0144027.t003

###### Identified VIPs ions.

![](pone.0144027.t003){#pone.0144027.t003g}

  Mass (*m/z*)    Category               Formula
  --------------- ---------------------- -------------------------
  **772.4843**    Glycerophospholipids   C~42~H~72~NO~8~P
  **670.3127**    Not identified         
  **970.5638**    Not identified         
  **975.5241**    Glycerophospholipids   C~46~H~82~O~16~P~2~
  **765.5005**    Glycerophospholipids   C~39~H~73~O~12~P
  **976.5331**    Glycerophospholipids   C~44~H~81~N~3~O~15~P~2~
  **614.3744**    Glycerophospholipids   C~30~H~58~NO~8~P
  **1020.6047**   Not identified         
  **898.5402**    Glycerophospholipids   C~50~H~86~NO~8~P
  **555.2986**    Sterol Lipids          C~27~H~48~O~8~S
  **962.5483**    Not identified         
  **516.2946**    Sterol Lipids          C~26~H~45~NO~7~S
  **872.5091**    Glycerophospholipids   C~47~H~80~NO~10~P
  **660.386**     Glycerophospholipids   C~31~H~60~NO~10~P
  **1098.6425**   Not identified         
  **820.4806**    Glycerophospholipids   C~43~H~76~NO~10~P

Discussion {#sec007}
==========

We detected clear differences in the serum lipid profile of healthy pregnant women compared to GDM patients and between milder (diet-treated) compared to more severe (AIT) forms of GDM.

The physiological dyslipidemia that occurs in normal pregnancy is apparently more intense in women with GDM, despite some controversies. Increased hyperlipidemia could be caused by a combination of IR associated with hormonal changes, such as decreased progesterone, prolactin and estradiol \[[@pone.0144027.ref009], [@pone.0144027.ref013]\].

To the best of our knowledge, this is the first study to evaluate the lipid fingerprint of GDM patients. A few studies have used this tool to assess the mechanisms involved in normal pregnancy and its complications. Durn et al. (2010) analyzed the myometrial prostanoid profile of women in labor and not in labor at term \[[@pone.0144027.ref024]\]. Other investigators reported significant differences in the lipid profile of syncytiotrophoblasts from placentas of women with preeclampsia and with recurrent abortion compared with healthy controls \[[@pone.0144027.ref025]\]. de Oliveira et al. (2012) identified lipid compounds in blood plasma from women with preeclampsia that could be associated with the disease \[[@pone.0144027.ref026]\]. This approach has also been used to investigate the role of lipids in Diabetes *Mellitus*. Recent studies with T2DM suggest that this approach is useful to characterize lipid changes in peripheral blood associated with the disease \[[@pone.0144027.ref016], [@pone.0144027.ref017]\].

Kaur et al. (2013) evaluated both the lipid and metabolic profiles of 69 patients with T2DM compared with 41 healthy individuals and reported hyper and hypo-represented lipids in the plasma of the diabetics, mostly glycerophospholipids (phosphatidylcholine, phosphatidylglycerol and phosphatidylethanolamine) and sphingolipids. The authors also reported that T2DM affects molecules involved in carbohydrate, amino acids and lipid metabolism \[[@pone.0144027.ref016]\].

Lipid profiling seems to bring more relevant information than gene expression analysis per se. Zhao et al. (2013) analyzed lipid profiles and gene expression in 84 T2DM and 60 healthy controls. While gene expression evaluations alone revealed no significant differences between patients, lipid profile analyses detected different characteristic features in each group. Lipid profiling can also contribute to the interpretation of gene expression results allowing the identification of biological pathways and suspected genes involved in insulin resistance \[[@pone.0144027.ref017]\].

Merzouk et al. (2000) reported altered lipid profiles in poorly controlled pregnant T1DM patients \[[@pone.0144027.ref027]\]. Changes in lipids in early pregnancy may be related with higher risks of IR and hyperglycemia later in gestation. On the other hand, GDM patients that require insulin therapy to achieve glycemic control have more severe clinical manifestations of the disease and higher risks for metabolic disorders after pregnancy \[[@pone.0144027.ref005], [@pone.0144027.ref006], [@pone.0144027.ref028]\].

Based on the lipid extraction protocol and ESI-(+)-MS method used in this study, we expected to find a considerable number of ions classified as Glycerophospholipids. Saccharolipids, Polyketides and Carnitine classes in SimLipid search were not included due the characteristics of the protocol. It was possible to identify ions in several lipid classes. Our approach did not allow the identification of the specific lipid that corresponds to each ion, but we were able to identify the lipid classes.

Most of the ions (63) belonged to the GP class. The most common GP in mammalian cell membrane are glycerophosphatidic acids, glycerophosphocholines, glycerophosphoethanolamines, glycerophosphoinositols, glycerophosphoglycerols, glycerophosphoserines, and cardiolipins \[[@pone.0144027.ref029]\]. GPs, key components of the cell membrane, are involved in several mechanisms including anti-inflammatory and immunomodulatory activities \[[@pone.0144027.ref030]\]. GPs also seem to have beneficial effects in the treatment of dyslipidemias, but it is still unclear which specific mechanisms and subclasses are involved in this process \[[@pone.0144027.ref031], [@pone.0144027.ref032]\].

Sterol Lipids were the second class most frequently observed in this study (15 ions). They are important constituents of the cell membrane, involved in cell growth and proliferation and are precursors of bile acids and steroid hormones \[[@pone.0144027.ref033]\]. Cholesterol is considered the major element of this class.

We also identified five ions in the Sphingolipids and Prenol Lipids. Sphingolipids are involved in the cascade of intracellular signaling and in cell recognition. Derivatives of glycosylated sphingolipid, called glycosphingolipids, are the class of more complex and structurally diverse SP, but there are other subclasses, such as sphingoid bases, ceramides and others \[[@pone.0144027.ref029], [@pone.0144027.ref034]\]. Some lipids of this class have currently been associated with glucose metabolism and insulin resistance \[[@pone.0144027.ref035], [@pone.0144027.ref036]\]. Prenol Lipids are vital for cell survival and are precursors of many vitamins, such as vitamin A and E \[[@pone.0144027.ref029]\].

Our analysis also detected Fatty Acyl (4 ions) and Glycerolipid (1 íon). Fatty Acyls are responsible for body energy and the formation of complex lipids \[[@pone.0144027.ref029]\]. This class of lipids is influenced by diet and insulin can block the release of these lipids. Moreover, obesity seems to increase free FA. Finally, Glycerolipids are involved in a large number of biochemical functions, from energy reserve to serving as precursors of intracellular signaling after activation of membrane receptors. This class of lipids is divided in subgroups, such as triacylglycerols (TAG) and diacylglycerols (DAG) \[[@pone.0144027.ref037]\]. TAGs are the major source of cellular energy, serving as a source of essential and non-essential fatty acids, as well as serving as precursors in the biosynthesis of phospholipids \[[@pone.0144027.ref038]\]. On the other hand, DAGs are intracellular messengers that have been identified as mediators of IR \[[@pone.0144027.ref039]\].

Due to technical limitations, it was not possible to classify all statistically significant ions. However, we were able to categorize most of the ions identified into a lipid classification. Nevertheless, the next step should be identify and quantify the specific ions that were differently presented in each group. We intend to perform MS/MS analysis of all VIP ions. After these tests we should be able to identify the most important ions to screen in order to characterize and understand the role of lipids in the physiopathology of GDM. This specific analysis is challenging because it requires a larger volume of serum, additional testing using other technical approaches and is very expensive.

Another point to be considered is that we did not collect fasting blood samples. This, in theory, could have affected our results. However, all samples were collected in the afternoon, within the first 2 hours after lunch thus reducing the possible heterogeneity related to this aspect. Moreover, all the patients with GDM were following exactly the same type of diet and therefore the caloric intake and composition of that meal was probably very similar.

Despite these limitations, this study was the first to use the lipid fingerprinting approach in women with GDM, supporting the relevant role of lipid profile in the pathogenesis of this disease.

There are marked differences in lipid fingerprinting between healthy pregnant women compared to those with GDM in the third trimester. Moreover, the lipid profile of women with more severe forms of GDM differs considerably from that of women with milder forms of GDM.

Historically, to optimize maternal and perinatal outcomes, obese and high risk pregnant women are counselled to follow healthy diets with controlled caloric intake and to exercise. However, the effects of these recommendations on metabolic (glycemic and lipid) parameters are still controversial. While some investigators reported significant changes in the lipid profile of women on low carbohydrate diets \[[@pone.0144027.ref040]--[@pone.0144027.ref042]\] and receiving insulin therapy \[[@pone.0144027.ref043], [@pone.0144027.ref044]\], other studies, including a systematic review, did not find a significant effect of these interventions on lipid metabolism \[[@pone.0144027.ref019], [@pone.0144027.ref045]--[@pone.0144027.ref047]\]. Thus, although it is possible that part of the differences in the lipid profiles of our groups could be due to the treatment itself, this hypothesis is not currently supported by evidence.

This study identified some lipids that should be further investigated to clarify the pathogenesis of GDM. Our results indicate that a lipid fingerprinting approach could be further developed and tested in the future as a potential new tool to help predict the risk of developing more severe forms of GDM.
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